Navigation Links
ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
Date:2/26/2008

growth in pancreatic and breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem cells." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3995:

"A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusresearch.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ material
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
6. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
7. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
8. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
9. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. ARIUS to present at Chinese Global Financial Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... NASDAQ: SHPG ) and Cincinnati Children,s Hospital ... collaboration for rare diseases. The goal of the collaboration ... treat rare diseases with high unmet medical need ... Children,s research expertise. As a nationally ranked hospital, ...
(Date:3/26/2015)... "In America," the popular news television program that airs in ... legendary film actor James Earl Jones, has announced that it ... , Botany is commonly described as the scientific study ... bit more complicated than that. Scientists and other professionals study ... the smallest bacteria known to man to the largest trees ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalystâ„¢ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... 18 Danube Pharmaceuticals, Inc., a,privately held biopharmaceutical ... innovative drugs for ophthalmology, is pleased,to announce the ... its Chief,Executive Officer., "I am honored and ... in its history as it advances its lead ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... will present at the,Jefferies & Co. 2nd Annual Healthcare ... Wednesday, June 25, 2008., An audio webcast of ... the webcast at: http://www.alexionpharm.com . An archived version ...
... June 18 HemoCue(R) AB, a,global point-of-care diagnostic ... Incorporated (NYSE: DGX ), today announced,that its ... point-of-care,test for screening for, diagnosing and monitoring microalbuminuria ... Food and Drug Administration (FDA). With,the FDA CLIA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... which has not been seen for nearly a century, has ... be in critical danger of extinction given that the only ... (Spain). A study reveals its characteristics and the reasons ... remains critically endangered. Researchers wants to restore this floral plant ...
... Mo. Plants do not have eyes or legs, yet ... from light. This ability, called phototropism, is controlled by a ... cells. In a paper published in The Plant Cell, ... the elusive role a critical protein plays in this molecular ...
... -- University of New Hampshire scientists have received National ... experiments can be applied to understand the behavior of ... investigate large-scale biological responses to climate and land-use change. ... natural resources and the environment (NREN) and assistant professor ...
Cached Biology News:The Murcian flower has been 'revived' after 100 years 2Protein plays role in helping plants see light 2UNH researchers receive NSF grant to 'scale up' stream ecology 2UNH researchers receive NSF grant to 'scale up' stream ecology 3
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, a ... are arrayed in quadruplicate for high-quality ... specific chip layout guarantee high validity ...
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, all extracellular ... classification, are arrayed in quadruplicate for ... a specific chip layout guarantee high ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... Reticulocyte Lysate Systems(a,b,c,d) offer researchers an ... a single-tube, coupled transcription/translation system. The ... process and reduce the time required ... Standard rabbit reticulocyte lysate translations (1) ...
Biology Products: